These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 11981375)

  • 1. Safety and tolerability of combination antiretroviral post-exposure prophylaxis in a population-based setting.
    Braitstein P; Chan K; Beardsell A; McLeod A; Montaner JS; O'Shaughnessy MV; Hogg RS
    J Acquir Immune Defic Syndr; 2002 Apr; 29(5):547-8. PubMed ID: 11981375
    [No Abstract]   [Full Text] [Related]  

  • 2. Tolerability of postexposure prophylaxis with zidovudine, lamivudine, and nelfinavir for human immunodeficiency virus infection.
    Rabaud C; Bevilacqua S; Beguinot I; Dorvaux V; Schuhmacher H; May T; Canton P
    Clin Infect Dis; 2001 May; 32(10):1494-5. PubMed ID: 11317252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term safety and efficacy of nevirapine, stavudine and lamivudine in a real-world setting.
    Shalit P; Farrell P; Lindgren P
    AIDS; 2001 Apr; 15(6):804-5. PubMed ID: 11371699
    [No Abstract]   [Full Text] [Related]  

  • 4. dNN study: stavudine, nelfinavir and nevirapine. Preliminary safety, activity and pharmacokinetic interactions.
    Skowron G
    Antivir Ther; 1998; 3 Suppl 4():61-2. PubMed ID: 10723513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of two HIV postexposure prophylaxis regimens among men who have sex with men in Amsterdam: adverse effects do not influence compliance.
    Sonder GJ; Prins JM; Regez RM; Brinkman K; Mulder JW; Veenstra J; Claessen FA; van den Hoek A
    Sex Transm Dis; 2010 Nov; 37(11):681-6. PubMed ID: 20644499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete reversibility of severe nucleoside-induced lipodystrophy.
    Strobel M; Muller P; Claudel P
    AIDS; 1999 Dec; 13(18):2606-7. PubMed ID: 10630538
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety and efficacy of two different triple drug combinations in which either lamivudine or didanosine were administered with stavudine plus indinavir.
    Villalba N; Gómez-Cano M; Casas E; Soriano V; Valencia E; González-Lahoz J
    AIDS; 1997 Dec; 11(15):1896-7. PubMed ID: 9412717
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES).
    Lowe SH; Wensing AM; Hassink EA; ten Kate RW; Richter C; Schreij G; Koopmans PP; Juttmann JR; van der Tweel I; Lange JM; Borleffs JC
    HIV Clin Trials; 2005; 6(5):235-45. PubMed ID: 16306030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicity and drug exposure in a quadruple drug regimen in HIV-1 infected patients participating in the ADAM study.
    Reijers MH; Weigel HM; Hart AA; Ten Kate RW; Mulder JW; Reiss P; Schuitemaker H; Hoetelmans RM; Weverling GJ; Lange JM
    AIDS; 2000 Jan; 14(1):59-67. PubMed ID: 10714568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence, side effects and efficacy of stavudine plus lamivudine plus nelfinavir in treatment-experienced HIV-infected patients.
    Roca B; Gómez CJ; Arnedo A
    J Infect; 2000 Jul; 41(1):50-4. PubMed ID: 10942640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe ototoxicity in a health care worker who received postexposure prophylaxis with stavudine, lamivudine, and nevirapine after occupational exposure to HIV.
    Rey D; L'Héritier A; Lang JM
    Clin Infect Dis; 2002 Feb; 34(3):418-9. PubMed ID: 11774091
    [No Abstract]   [Full Text] [Related]  

  • 12. Renal tubular acidosis and hypophosphataemia after treatment with nucleoside reverse transcriptase inhibitors.
    Morris AA; Baudouin SV; Snow MH
    AIDS; 2001 Jan; 15(1):140-1. PubMed ID: 11192863
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug safety evaluation profile of stavudine plus lamivudine for HIV-1/AIDS infection.
    Mateo MG; Gutierrez Mdel M; Vidal F; Domingo P
    Expert Opin Drug Saf; 2012 May; 11(3):473-85. PubMed ID: 22468613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiretroviral rounds. When success is a pain.
    Bartlett JG; del Rio C
    AIDS Clin Care; 2001 Aug; 13(8):74-5. PubMed ID: 11547461
    [No Abstract]   [Full Text] [Related]  

  • 15. Hypercholesterolemia in a health care worker receiving thyroxine after postexposure prophylaxis for human immunodeficiency virus infection.
    Nerad JL; Kessler HA
    Clin Infect Dis; 2001 Jun; 32(11):1635-6. PubMed ID: 11340537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.
    Murphy RL; Brun S; Hicks C; Eron JJ; Gulick R; King M; White AC; Benson C; Thompson M; Kessler HA; Hammer S; Bertz R; Hsu A; Japour A; Sun E
    AIDS; 2001 Jan; 15(1):F1-9. PubMed ID: 11192874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lamivudine 300 mg QD versus continued lamivudine 150 mg BID with stavudine and a protease inhibitor in suppressed patients.
    Sension MG; Bellos NC; Johnson J; Sepulveda GE; DeJesus E; Santana JL; Ames MH; Goodwin SD
    HIV Clin Trials; 2002; 3(5):361-70. PubMed ID: 12407485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ongoing open-label trials of triple therapy with stavudine and lamivudine or stavudine and didanosine plus nelfinavir.
    Anderson RD
    Antivir Ther; 1998; 3 Suppl 4():63-4. PubMed ID: 10723514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lactic acid levels in children perinatally treated with antiretroviral agents to prevent HIV transmission.
    Giaquinto C; De Romeo A; Giacomet V; Rampon O; Ruga E; Burlina A; De Rossi A; Sturkenboom M; D'Elia R
    AIDS; 2001 May; 15(8):1074-5. PubMed ID: 11399997
    [No Abstract]   [Full Text] [Related]  

  • 20. Addition of cyclophosphamide to antiretroviral therapy does not diminish the cellular reservoir in HIV-infected persons.
    Bartlett JA; Miralles GD; Sevin AD; Silberman M; Pruitt SK; Ottinger J; Gryszowska V; Fiscus SA; Bucy RP;
    AIDS Res Hum Retroviruses; 2002 May; 18(8):535-43. PubMed ID: 12036483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.